Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437749 | 0.91 | ADRA2C (0.38) | ADRA2CADRA1AADRA1BKDM1AMAOA | |
| SCHEMBL3780898 | 0.86 | ADRA2C (0.39) | ADRA2CADRA1AADRA1BKDM1AMAOA | |
| SCHEMBL4443621 | 0.81 | TGM2 (0.30) | — | |
| SCHEMBL3364600 | 0.80 | ADRA2C (0.39) | ADRA2CADRA1AADRA1BHTR6 | |
| SCHEMBL957737 | 0.72 | ADRA2C (0.41) | ADRA2CADRA1AADRA1BHTR6 | |
| SCHEMBL4437406 | 0.72 | TGM2 (0.32) | CA2CA1 | |
| Hydrochloric Acid SCHEMBL3362498 | 0.71 | ADRA2C (0.40) | ADRA2CADRA1AADRA1B | |
| SCHEMBL955620 | 0.70 | ADRA2C (0.42) | ADRA2CADRA1AADRA1B | |
| SCHEMBL3782008 | 0.70 | ADRA2C (0.40) | ADRA2CADRA1AADRA1B | |
| SCHEMBL3782011 | 0.70 | ADRA2C (0.40) | ADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |